Literature DB >> 27058243

The Pathology of Acute Liver Failure.

Jay H Lefkowitch1.   

Abstract

Acute liver failure (ALF) is a rare and severe liver disease that usually develops in 8 weeks or less in individuals without preexisting liver disease. Its chief causes worldwide are hepatitis virus infections (hepatitis A, B, and E) and drug hepatotoxicity (particularly intentional or unintentional acetaminophen toxicity). Massive hepatic necrosis is often seen in liver specimens in ALF and features marked loss of hepatocytes, variable degrees of inflammation, and a stereotypic proliferation of bile ductular structures (neocholangioles) derived from activated periportal hepatic progenitor cells. This paper reviews the liver pathology in ALF, including forms of zonal necrosis and their etiologies.

Entities:  

Mesh:

Year:  2016        PMID: 27058243     DOI: 10.1097/PAP.0000000000000112

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  10 in total

Review 1.  Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy.

Authors:  Shannan R Tujios; William M Lee
Journal:  Liver Int       Date:  2017-09-18       Impact factor: 5.828

Review 2.  An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.

Authors:  Javier De Las Heras; Luis Aldámiz-Echevarría; María-Luz Martínez-Chantar; Teresa C Delgado
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-11-28       Impact factor: 4.481

3.  Verapamil inhibits early acute liver failure through suppressing the NLRP3 inflammasome pathway.

Authors:  Mingying Han; Shouzhou Li; Lanrong Li
Journal:  J Cell Mol Med       Date:  2021-05-24       Impact factor: 5.310

Review 4.  Therapeutic plasma exchange in children with acute liver failure (ALF): is it time for incorporation into the ALF armamentarium?

Authors:  Emma C Alexander; Akash Deep
Journal:  Pediatr Nephrol       Date:  2021-10-14       Impact factor: 3.651

5.  Liver Fibrosis Markers Improve Prediction of Outcome in Non-Acetaminophen-Associated Acute Liver Failure.

Authors:  Aya Ugamura; Po-Sung Chu; Nobuhiro Nakamoto; Nobuhito Taniki; Keisuke Ojiro; Taizo Hibi; Masahiro Shinoda; Hideaki Obara; Yohei Masugi; Akihiro Yamaguchi; Shunsuke Shiba; Rei Morikawa; Shingo Usui; Hirotoshi Ebinuma; Yuko Kitagawa; Hidetsugu Saito; Takanori Kanai
Journal:  Hepatol Commun       Date:  2018-09-21

Review 6.  Protective effect of isoflavones and triterpenoid saponins from pueraria lobata on liver diseases: A review.

Authors:  Heng He; Shuwei Peng; Xu Song; Renyong Jia; Yuanfeng Zou; Lixia Li; Zhongqiong Yin
Journal:  Food Sci Nutr       Date:  2021-12-10       Impact factor: 2.863

7.  Collagen and elastic fibres in acute and chronic liver injury.

Authors:  Andrew Hall; Corina Cotoi; Tu Vinh Luong; Jennifer Watkins; Prithi Bhathal; Alberto Quaglia
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

8.  Clarithromycin-Associated Acute Liver Failure Leading to Fatal, Massive Upper Gastrointestinal Hemorrhage from Profound Coagulopathy: Case Report and Systematic Literature Review.

Authors:  Ahmed I Edhi; Seifeldin Hakim; Christienne Shams; Damanpreet Bedi; Mitual Amin; Mitchell S Cappell
Journal:  Case Reports Hepatol       Date:  2020-02-18

Review 9.  Liver Progenitor Cells in Massive Hepatic Necrosis-How Can a Patient Survive Acute Liver Failure?

Authors:  Tao Lin; Rilu Feng; Roman Liebe; Hong-Lei Weng
Journal:  Biomolecules       Date:  2022-01-02

10.  Menstrual blood-derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice.

Authors:  Dazhi Chen; Ruichao Zeng; Guigen Teng; Chao Cai; Tongtong Pan; Hanxiao Tu; Hongwei Lin; Qingjing Du; Huahong Wang; Yongping Chen
Journal:  J Gastroenterol Hepatol       Date:  2021-04-05       Impact factor: 4.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.